Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421849 | 1.00 | L3MBTL1 (0.34) | L3MBTL1HTR2CSLC6A4PTPN1KLK7 | |
| SCHEMBL421850 | 1.00 | L3MBTL1 (0.34) | L3MBTL1HTR2CSLC6A4PTPN1KLK7 | |
| SCHEMBL10120963 | 0.86 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL10120771 | 0.74 | L3MBTL1 (0.34) | L3MBTL1NPSR1 | |
| SCHEMBL418551 | 0.72 | — | — | |
| SCHEMBL10143671 | 0.69 | — | — | |
| SCHEMBL10120954 | 0.68 | ASGR1 (0.32) | — | |
| SCHEMBL10120972 | 0.67 | L3MBTL1 (0.34) | L3MBTL1HTR2CSLC6A4PTPN1 | |
| SCHEMBL418381 | 0.65 | RNASEH1 (0.41) | L3MBTL1PTPN1 | |
| SCHEMBL418380 | 0.65 | RNASEH1 (0.41) | L3MBTL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | L3MBTL1 108/4885HTR2C 4813/4885SLC6A4 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.